JNJ's Janssen unit gets Invega approval |
|
|
|
Published
:
Fri, 27 Apr 2007 20:30
|
NEW BRUNSWICK, N.J. (AP) - Diversified health-care products maker Johnson & Johnson on Friday said its Janssen LP unit received Food and Drug Administration additional approvals for its schizophrenia drug Invega.The drug was already approved for uses as a short-term treatment. The FDA decision adds an indication for use as a long-term treatment.Shares of JNJ fell 4 cents to $64.20 on the New York Stock Exchange in afternoon trading.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2149.46 |
+23.41 (
1.09 %)
|
| SYMBOL (
2010-02-09 ) |
| LAST |
CHANGE
|
|
RIO TINTO
(
9:38am )
|
|
3195.00 |
+129.50 (
4.20 %)
|
|
XSTRATA
(
9:38am )
|
|
1032.50 |
+48.70 (
4.87 %)
|
| SYMBOL (
2010-02-09 )
|
| LAST |
CHANGE
|
|
IBM
(
9:34am ) |
|
123.24 |
+1.36 (
1.11 %)
|
| SYMBOL (
2010-02-09 )
|
| LAST |
CHANGE
|
|
GOOGLE
(
9:59am ) |
|
538.70 |
+5.23 (
0.97 %)
|
|
|
Print this Story
J&J gets subpoenas over three drugs 